Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000899243-20-034201
Filing Date
2020-12-16
Accepted
2020-12-16 20:07:17
Documents
2
Period of Report
2020-12-14

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 6961
2 EX-99.1 DOCUMENT attachment1.htm EX-99.1 1345
  Complete submission text file 0000899243-20-034201.txt   10720
Mailing Address LILLY CORPORATE CENTER DROP CODE 1094 INDIANAPOLIS IN 46285
Business Address LILLY CORPORATE CTR DROP CODE 1094 INDIANAPOLIS IN 46285 3172762000
ELI LILLY & Co (Reporting) CIK: 0000059478 (see all company filings)

State of Incorp.: IN | Fiscal Year End: 1231
Type: 3 | Act: 34 | File No.: 001-38939 | Film No.: 201393907
SIC: 2834 Pharmaceutical Preparations

Mailing Address 430 EAST 29TH STREET, SUITE 940 NEW YORK NY 10016
Business Address 430 EAST 29TH STREET, SUITE 940 NEW YORK NY 10016 917-336-9310
Prevail Therapeutics Inc. (Issuer) CIK: 0001714798 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address C/O ELI LILLY AND COMPANY GLOBAL HEADQUARTERS, LILLY CORPORATE CENTER INDIANAPOLIS IN 46285
Business Address C/O ELI LILLY AND COMPANY GLOBAL HEADQUARTERS, LILLY CORPORATE CENTER INDIANAPOLIS IN 46285 (317) 276-2000
Tyto Acquisition Corp (Reporting) CIK: 0001836675 (see all company filings)

State of Incorp.: DE | Fiscal Year End: 1231
Type: 3 | Act: 34 | File No.: 001-38939 | Film No.: 201393906